Centanafadine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Centanafadine
Centanafadine.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC15H15N
Molar mass209.28 g/mol g·mol−1
3D model (JSmol)
Centanafadine [1]
Site IC50 (nM) Action Ref
SERT 83 nM Blocker [1]
NET 6 nM Blocker [1]
DAT 38 nM Blocker [1]

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively.[1][2][3][4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.[7] As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.[8]

See also[edit]

References[edit]

  1. ^ a b c d e "Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.
  2. ^ "3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.
  3. ^ "EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance.
  4. ^ Frank P. Bymaster; Krystyna Golembiowska; Magdalena Kowalska; Yong Kee Choi; Frank I. Tarazi (June 2012). "Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder". Synapse. 66 (6): 522–532. doi:10.1002/syn.21538. PMID 22298359.
  5. ^ "Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.
  6. ^ "EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.
  7. ^ "Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.
  8. ^ "Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.

External links[edit]